- |||||||||| Pravitinib (carboxyamidotriazole orotate) / Tactical Therap
Enrollment closed, Trial primary completion date, Combination therapy, Metastases: Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar (clinicaltrials.gov) - Sep 22, 2023
P1, N=100, Active, not recruiting,
Trial completion date: Jan 2024 --> Jan 2026 | Trial primary completion date: Jan 2024 --> Jan 2025 Unknown status --> Active, not recruiting | Trial primary completion date: Jun 2018 --> Jan 2024
- |||||||||| Avastin (bevacizumab) / Roche, pravitinib (CTO) / Tactical Therap
Clinical, P1 data, Journal: Multicenter Phase IB Trial of Carboxyamidotriazole Orotate and Temozolomide for Recurrent and Newly Diagnosed Glioblastoma and Other Anaplastic Gliomas. (Pubmed Central) - Aug 7, 2019
Gene sequencing disclosed a high rate of responses among EGFR-amplified tumors ( P = .005), with mechanisms of acquired resistance possibly involving mutations in mismatch-repair genes and/or downstream components TSC2, NF1, NF2, PTEN, and PIK3CA. Conclusion CTO can be combined safely with TMZ or chemoradiation in GBM and anaplastic gliomas, displaying favorable brain penetration and promising signals of activity in this difficult-to-treat population.
- |||||||||| Pravitinib (carboxyamidotriazole orotate) / Tactical Therap
Enrollment closed, Trial primary completion date, Combination therapy, Metastases: Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar (clinicaltrials.gov) - Jan 6, 2017
P1, N=100, Active, not recruiting,
Conclusion CTO can be combined safely with TMZ or chemoradiation in GBM and anaplastic gliomas, displaying favorable brain penetration and promising signals of activity in this difficult-to-treat population. Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2015 --> Jun 2018
- |||||||||| Avastin (bevacizumab) / Roche, Pravitinib (carboxyamidotriazole orotate) / Tactical Therap
Enrollment change, Trial termination, Trial primary completion date, Combination therapy: Ph 1/2 CTO With Lomustine for Bevacizumab-Naive Recurrent Glioma (clinicaltrials.gov) - Jun 16, 2016
P1/2, N=9, Terminated,
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2015 --> Jun 2018 N=138 --> 9 | Suspended --> Terminated | Trial primary completion date: Apr 2017 --> Mar 2015; This study was terminated early due to funding issues prior to completion of phase I
- |||||||||| Avastin (bevacizumab) / Roche, Pravitinib (carboxyamidotriazole orotate) / Tactical Therap
Enrollment change, Trial termination, Trial primary completion date, Combination therapy: Phase 1/2 CTO + Bevacizumab for Recurrent Glioma Post-Bevacizumab Failure (clinicaltrials.gov) - Feb 21, 2016
P1/2, N=17, Terminated,
N=138 --> 9 | Suspended --> Terminated | Trial primary completion date: Apr 2017 --> Mar 2015; This study was terminated early due to funding issues prior to completion of phase I N=68 --> 17 | Suspended --> Terminated | Trial primary completion date: May 2016 --> Jul 2015; Study terminated early due to funding reasons prior to completing Phase 1
- |||||||||| Avastin (bevacizumab) / Roche, Pravitinib (carboxyamidotriazole orotate) / Tactical Therap
Trial suspension, Combination therapy: Ph 1/2 CTO With Lomustine for Bevacizumab-Naive Recurrent Glioma (clinicaltrials.gov) - Jun 11, 2015
P1/2, N=138, Suspended,
N=68 --> 17 | Suspended --> Terminated | Trial primary completion date: May 2016 --> Jul 2015; Study terminated early due to funding reasons prior to completing Phase 1 Recruiting --> Suspended
- |||||||||| Avastin (bevacizumab) / Roche, Pravitinib (carboxyamidotriazole orotate) / Tactical Therap
Trial initiation date, Combination therapy: Ph 1/2 CTO With Lomustine for Bevacizumab-Naive Recurrent Glioma (clinicaltrials.gov) - May 27, 2014
P1/2, N=138, Recruiting,
Trial primary completion date: Jun 2014 --> Jun 2015 Initiation date: Dec 2013 --> May 2014
- |||||||||| Avastin (bevacizumab) / Roche, Pravitinib (carboxyamidotriazole orotate) / Tactical Therap
Enrollment open, Combination therapy: Ph 1/2 CTO With Lomustine for Bevacizumab-Naive Recurrent Glioma (clinicaltrials.gov) - May 27, 2014
P1/2, N=138, Recruiting,
Initiation date: Dec 2013 --> May 2014 Not yet recruiting --> Recruiting
|
